Lambert Tim
Office for Psychiatric Evaluation and Educational Newmedia, University of Melbourne and Orygen Youth Health, Parkville, Vic., Australia.
Australas Psychiatry. 2006 Mar;14(1):38-42. doi: 10.1080/j.1440-1665.2006.02243.x.
As new psychopharmacological agents for the management of schizophrenia are introduced into clinical practice, inappropriate patient selection may often lead to disappointing outcomes for the patient, the family and services. Recently, the first and only long-acting novel antipsychotic was made available in Australia. Based on criteria used in a large clinical network in Victoria, this paper sets out to present six selection profiles for patients with schizophrenia who may be suitable candidates for treatment with this class of medication.
Optimizing outcome for patients with enduring psychotic disorders involves enabling a stable psychopharmacological platform upon which to build a psychosocial therapies programme. Too often, problems with adherence undermine the recovery process. Long-acting novel antipsychotics ensure adherence, with all the advantages inherent in second-generation antipsychotics. Identifying patients a priori who might best respond to the long-acting novel antipsychotics may lead to improving the efficiency of the recovery process.
随着用于治疗精神分裂症的新型精神药物被引入临床实践，不恰当的患者选择往往会给患者、家庭和医疗服务带来令人失望的结果。最近，澳大利亚上市了首款也是唯一一款长效新型抗精神病药物。基于维多利亚州一个大型临床网络所使用的标准，本文旨在为可能适合使用这类药物治疗的精神分裂症患者呈现六种选择概况。
优化持续性精神障碍患者的治疗效果需要建立一个稳定的精神药物治疗平台，在此基础上开展心理社会治疗项目。依从性问题常常会破坏康复进程。长效新型抗精神病药物可确保依从性，并具备第二代抗精神病药物的所有固有优势。预先确定可能对长效新型抗精神病药物反应最佳的患者，可能会提高康复进程的效率。
